The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry.
Annelie A H MustersConor BroderickDavid Prieto-MerinoAndrea ChiricozziGiovanni DamianiKetty PerisSandipan DharAbhishek DeEsther E FreemanBernd W M ArentsTim BurtonAngela Leigh-Ann L BosmaChing-Chi ChiGodfrey FletcherAaron Mark DruckerKenji KabashimaEmilie F de MonchyMaitreyee PandaDmitri Robert WallChristian L VestergaardEmmanuel MahéLaura BonzanoLeila KattachMaddalena NapolitanoMaría Fernanda Ordoñez-RubianoEva HaufeCataldo PatrunoAlan D IrvinePhyllis I SpulsCarsten FlohrPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Overall, the risk of COVID-19 complications appears low in patients with AD, even when treated with systemic immunomodulatory agents. Dupilumab monotherapy was associated with lower hospitalization than other therapies. Combination systemic treatment, particularly combinations including systemic corticosteroids, was associated with the highest risk of severe COVID-19.